Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224874 · ClinicalTrials.gov registry record · Phase 2
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
A Phase 2 study of Graft Vs Host Disease and Immune System Disorders, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 19
- Study locations
NCT00224874 is a Phase 2 study of Graft Vs Host Disease and Immune System Disorders that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 180 participants, above the 133-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (35% higher). The trial reports 19 study locations across 16 states.
The verdict
NCT00224874, a Phase 2 study of Graft Vs Host Disease and Immune System Disorders, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 19
- Study locations
Study Summary
The study is a randomized Phase II, four arm treatment trial. The primary purpose of the study is to define new agents with promising activity against acute graft-versus-host disease (GVHD) suitable for testing against corticosteroids alone in a subsequent Phase III trial.
Conditions Studied
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Pentostatin
- DRUG Etanercept
- DRUG Denileukin Diftitox
Study Locations (19)
California
- City of Hope National Medical Center - Duarte
- University of California - San Diego
- Stanford Hospital and Clinics - Stanford
Texas
- University of Texas/MD Anderson CRC - Houston
- Texas Transplant Institute - San Antonio
Florida
- University of Florida College of Medicine (Shands) - Gainesville
Maryland
- Johns Hopkins/SKCCC - Baltimore
Massachusetts
- DFCI/Brigham & Women's Hospital - Boston
Michigan
- University of Michigan Medical Center - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Missouri
- Washington University/Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2005-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224874
The ClinicalTrials.gov registry entry for NCT00224874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 133-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (35% higher). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 4 interventions - of which Mycophenolate Mofetil is the first listed.
NCT00224874 reports 19 study locations spanning 16 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT00224874 about?
NCT00224874 is a clinical study titled "Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)". The study is a randomized Phase II, four arm treatment trial. The primary purpose of the study is to define new agents with promising activity against acute graft-versus-host disease (GVHD) suitable for testing against corticosteroids alone in a subsequent Phase III trial.
What is the current status of trial NCT00224874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2005-09. Estimated completion is 2012-06.
What conditions does trial NCT00224874 study?
This clinical trial studies the following conditions: Graft Vs Host Disease, Immune System Disorders.
What interventions are being tested in trial NCT00224874?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Pentostatin (DRUG), Etanercept (DRUG), Denileukin Diftitox (DRUG).
Who is sponsoring clinical trial NCT00224874?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00224874 being conducted?
This trial has 19 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
RECRUITING · Phase 2
-
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
ACTIVE NOT RECRUITING · Phase 2
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.